AstraZeneca PLC
AZNNYSEHealthcare● Active
$181.55
$-4.40(-2.37%)
Market Cap$281.6B
P/E Ratio—
52W High$212.71
52W Low$137.22
AstraZeneca PLC（AZN）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · AZN · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $10.22B | $8.69B | $6.90B | $2.50B | ($0.27B) |
| Depreciation & Amort. | $5.73B | $5.07B | $4.93B | $5.48B | $6.53B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.58B | $0.62B | $0.61B |
| Change in Working Capital | ($1.16B) | ($0.89B) | $0.30B | $3.76B | $2.02B |
| Net Cash from Operations | $14.57B | $11.86B | $10.35B | $9.81B | $5.96B |
| Investing Activities | |||||
| Capital Expenditure | ($2.81B) | ($4.59B) | ($3.78B) | ($2.57B) | ($2.20B) |
| Purchases of Investments | $0.00B | ($0.10B) | ($0.14B) | ($0.16B) | ($0.18B) |
| Sales of Investments | $0.00B | $0.11B | $0.13B | $0.04B | $0.10B |
| Net Cash from Investing | ($6.81B) | ($7.98B) | ($4.06B) | ($2.96B) | ($11.06B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.72B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | ($5.08B) | ($4.63B) | ($4.48B) | ($4.36B) | ($3.86B) |
| Debt Issued / Repaid | ($1.69B) | $1.81B | ($0.96B) | ($1.20B) | $7.89B |
| Net Cash from Financing | ($7.54B) | ($4.00B) | ($6.57B) | ($6.82B) | $3.65B |
| Free Cash Flow | |||||
| Free Cash Flow | $11.77B | $7.28B | $6.57B | $7.24B | $3.76B |
| FCF Margin %(computed) | 20.03% | 13.45% | 14.33% | 16.32% | 10.06% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解AstraZeneca PLC
关于AstraZeneca PLC（AZN）现金流量表
AstraZeneca PLC 2025财年经营活动现金流$14.57B，自由现金流$11.77B（FCF利润率20.03%），资本支出($2.81B)。
常见问题
AZN · 4 问AstraZeneca PLC 2025财年自由现金流$11.77B，同比up61.7%。
AZN free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10